MAPT and Alzheimer disease: Yet, evidence in human studies overwhelmingly stem from cross-sectional studies, and a biologically plausible cascade model that incorporates these individual findings and can link soluble p-tau with downstream tau aggregation and clinical manifestations across the entire AD spectrum is still missing.